Personal CFO Solutions’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$206K	Sell	21,667 -40,733	-65%	-$316K	0.03%	502
2025 Q4	$487K	Buy	62,400 +212	+0.3%	+$1.53K	0.08%	242
2025 Q3	$472K	Hold	62,188	–	–	0.08%	240
2025 Q2	$557K	Hold	62,188	–	–	0.1%	198
2025 Q1	$466K	Buy	62,188 +672	+1%	+$5.42K	0.09%	218
2024 Q4	$463K	Sell	61,516 -215	-0.3%	-$1.63K	0.09%	219
2024 Q3	$469K	Hold	61,731	–	–	0.07%	278
2024 Q2	$381K	Sell	61,731 -5,000	-7%	-$27.6K	0.06%	315
2024 Q1	$339K	Buy	66,731 +428	+0.6%	+$2.41K	0.05%	361
2023 Q4	$397K	Sell	66,303 -453	-0.7%	-$2.63K	0.07%	293
2023 Q3	$473K	Hold	66,756	–	–	0.09%	205
2023 Q2	$470K	Sell	66,756 -1,000	-1%	-$8.03K	0.1%	214
2023 Q1	$565K	Buy	67,756 +366	+0.5%	+$3.52K	0.12%	172
2022 Q4	$774K	Hold	67,390	–	–	0.16%	118
2022 Q3	$849K	Buy	67,390 +302	+0.5%	+$3.89K	0.21%	88
2022 Q2	$710K	Sell	67,088 -42,100	-39%	-$434K	0.17%	109
2022 Q1	$1.77M	Hold	109,188	–	–	0.35%	48
2021 Q4	$1.51M	Hold	109,188	–	–	0.28%	64
2021 Q3	$1.57M	Sell	109,188 -2,490	-2%	-$39.3K	0.32%	58
2021 Q2	$1.77M	Sell	111,678 -10,000	-8%	-$136K	0.36%	54
2021 Q1	$1.24M	Buy	121,678 +16,500	+16%	+$170K	0.27%	73
2020 Q4	$784K	Buy	105,178 +14,000	+15%	+$72.2K	0.19%	106
2020 Q3	$0	Buy	91,178 +8,500	+10%	+$36.4K	﹤0.01%	155
2020 Q2	$394K	Sell	82,678 -4,400	-5%	-$17.6K	0.12%	164
2020 Q1	$174K	Buy	87,078 +55,078	+172%	+$152K	0.06%	249
2019 Q4	$110K	Buy	+32,000	New	+$80.5K	0.03%	330